|
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Wounds Overview 11 Therapeutics Development 12 An Overview of Pipeline Products for Wounds 12 Wounds Therapeutics under Development by Companies 14 Wounds Therapeutics under Investigation by Universities/Institutes 17 Late Stage Products 19 Comparative Analysis 19 Mid Clinical Stage Products 20 Comparative Analysis 20 Early Clinical Stage Products 21 Comparative Analysis 21 Pre-Clinical Stage Products 22 Comparative Analysis 22 Wounds Therapeutics – Products under Development by Companies 23 Wounds Therapeutics – Products under Investigation by Universities/Institutes 24 Companies Involved in Wounds Therapeutics Development 25 Sanofi-Aventis 25 Biotec Pharmacon ASA 26 CardioVascular BioTherapeutics, Inc. 27 Nanotherapeutics, Inc. 28 NexMed, Inc. 29 Bio3 Research S.r.l 30 Renovo Group Plc 31 CytoTools AG 32 AnaMar Medical AB 33 Foamix Ltd. 34 Garnet BioTherapeutics 35 Akebia Therapeutics, Inc. 36 Glycotex, Inc. 37 Phage Biotechnology Corporation 38 AndroScience Corporation 39 NovaLead Pharma Pvt. Ltd. 40 BRIDGE BIORESEARCH PLC 41 ImmuneRegen BioSciences, Inc. 42 CoDa Therapeutics, Inc. 43 Innocoll, Inc. 44 Beech Tree Labs, Inc. 45 Wounds – Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 53 Juvidex - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 CVBT-141B - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Homspera - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 NanoDOX - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CTR-2 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Vitaros - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 GLYC-101 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 GLYC-101 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 ASC-J9 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PXL01 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 DermaPro CI 05 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 FGF-1 141 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 GBT009 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Autologous Platelet Gel - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Autologous Platelet Gel - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Soluble Beta Glucan - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Nexagon - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 FXFM244 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 DAC N-055 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Cogenzia - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Doxycycline - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 rhPDGF-BB - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 ColMod - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Adalimumab1 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Autologous Platelet Rich Plasma + Keratinocyte suspension - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 87 Lidocaine + Epinephrine + Tetracaine - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Cultured Autologous Keratinocytes - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Betadine - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 RNS60 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 KUR-212 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 RayVa - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Vasculotide - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Antimicrobial Peptide LL-37 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 AKB-4924 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 BBR-012 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 HO/07/09 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 HO/03/06 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Neurotensin - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Bactericidal Venom-Based Polypeptides - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Botox - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Wounds Therapeutics – Drug Profile Updates 104 Wounds Therapeutics – Discontinued Products 114 Wounds Therapeutics - Dormant Products 115 Wounds – Product Development Milestones 116 Featured News & Press Releases 116 Jan 19, 2012: Bridge BioResearch Receives Approval For Phase IIa Trial Protocol Of Isoniazide 116 Jan 09, 2012: NovaBay Pharmaceuticals Announces Strategic Marketing Agreement For NeutroPhase In China 116 Mar 18, 2011: National In Association With Globe Labs To Enter Into Discussion On Clinical Trials Protocols For GLB333 117 Mar 11, 2011: National Pharmaceuticals's GLB333 Receives Financial Grant 117 Feb 14, 2011: Pergamum To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 117 Jan 21, 2011: Biotec Pharmacon Receives Promising Interim Results From Animal Study 118 Nov 23, 2010: Phase IIa Completed For Dermapro With Excellent Safety Profile And Very Good Tolerance 119 Apr 12, 2010: PharmaSurgics To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 119 Dec 04, 2009: Pharmasurgics To Begin Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 120 Jul 14, 2009: PXL01 For The Treatment Of Post-Surgical Adhesion Formation Completes Phase I Clinical Study 120 Appendix 121 Methodology 121 Coverage 121 Secondary Research 121 Primary Research 121 Expert Panel Validation 121 Contact Us 122 Disclaimer 122
|